• Introduction
  • Why Almac?
  • People
  • Facilities
• Biomarker Discovery and Validation
  • Companion Diagnostics
  • Pharmacodynamic Biomarkers
  • Prognostic tests
  • Drug Repositioning
  • Consultancy
• Bioinformatics Solutions
  • Gene Selection
  • Signature generation
  • Functional analysis
• Genomic services
  • Gene Expression and SNP analysis
  • qPCR and cell line modelling
  • Bioinformatics
• Cancer DSA™
  • Unique Content
  • Work with FFPE and fresh frozen tissue
  • Discover Targets, signatures and answers
• Resources
  • Technical Documentation
  • Posters and presentations
  • Publications

Discover Targets, signatures and answers

Almac are involved in a range of collaborations using Colorectal Cancer DSA™ and Breast Cancer DSA™ research tools to address numerous and diverse clinical research objectives.

We are currently working on several studies targeting the identification of new targets for drug development and drug rescue and developing genetic signatures for diagnostic and prognostic development, patient selection and patient stratification.

Colorectal Cancer DSA™, Breast Cancer DSA™ and Lung Cancer DSA™ are available now to researchers in pharma, biotech and academia. Prostate Cancer DSA™ and Ovarian Cancer DSA™ will be launched later this year.